- Report
- April 2025
- 50 Pages
Global
From €2476EUR$2,650USD£2,094GBP
- Report
- August 2024
- 138 Pages
Global
From €2802EUR$2,999USD£2,370GBP
- Report
- August 2024
- 187 Pages
Global
From €4204EUR$4,500USD£3,556GBP
- Report
- September 2019
- 30 Pages
China
From €2055EUR$2,200USD£1,739GBP
- Report
- March 2024
- 257 Pages
Global
From €7007EUR$7,500USD£5,927GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1168EUR$1,250USD£988GBP
- Report
- April 2023
- 145 Pages
Global
From €7007EUR$7,500USD£5,927GBP
- Report
- February 2024
- 73 Pages
Global
From €3500EUR$4,013USD£3,065GBP
- Report
- January 2019
- 51 Pages
Global
From €9342EUR$10,000USD£7,903GBP
- Report
- February 2024
- 96 Pages
Global
From €3500EUR$4,013USD£3,065GBP
- Report
- April 2023
- 86 Pages
Global
From €3500EUR$4,013USD£3,065GBP
- Report
- April 2025
- 50 Pages
Global
From €2476EUR$2,650USD£2,094GBP
Vincristine is a chemotherapy drug used to treat a variety of leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). It is a type of vinca alkaloid, derived from the Madagascar periwinkle plant, and works by inhibiting the growth of cancer cells. Vincristine is typically administered intravenously, and is often used in combination with other drugs to maximize its effectiveness.
Vincristine is a widely used drug in the treatment of leukemias, and is often prescribed in combination with other drugs. It is generally well-tolerated, with few side effects. However, it can cause peripheral neuropathy, which can lead to numbness and tingling in the hands and feet.
The vincristine market is highly competitive, with many companies offering generic versions of the drug. Some of the major players in the market include Pfizer, Novartis, Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more